Search

Displaying results 1971 - 1980 of 10000 in total
  1. Target

    Alpha-ketoglutarate-dependent dioxygenase FTO

    go.drugbank.com/bio_entities/BE0005795
    TargetHumans

    Mediates demethylation of N(6),2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed:28002401, PubMed:30197295) … Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed:30197295).

    Synonyms: mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO, U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO
  2. Target

    Nuclear factor NF-kappa-B complex

    go.drugbank.com/bio_entities/BE0009554
    TargetHumans

    NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. … NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family.

    Synonyms: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1
  3. Drug

    Relatlimab

    go.drugbank.com/drugs/DB14851
    ApprovedInvestigational

    [A246155] Relatlimab received FDA approval in March 2022, alongside the PD-1 inhibitor [nivolumab] in the combination product Opdualag (Bristol-Myers Squibb), for the treatment of unresectable or metastatic … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia

    Mixtures: OPDUALAG® SOLUCION INYECTABLECategories: Lymphocyte Activation Gene-3 Blocker
  4. Drug

    Cupric oxide

    go.drugbank.com/drugs/DB11134
    Approved

    Cupric oxide, or copper (II) oxide, is an inorganic compound with the chemical formula CuO. … Copper(II) oxide nanoparticles (NPCuO) have industrial applications as antimicrobial agents in textiles and paints, and catalysts in organic synthesis [A32656].

    Mixtures: I-care Multivitamin and Multimineral Tablets, Escavite D
  5. Drug

    Inositol

    go.drugbank.com/drugs/DB13178
    ApprovedInvestigationalWithdrawn

    It is considered a pseudovitamin as it is a molecule that does not qualify to be an essential vitamin because even though its presence is vital in the body, a deficiency in this molecule does not translate … [L1113] By the FDA, inositol is considered in the list of specific substances affirmed as generally recognized as safe (GRAS).[L2561]

    Mixtures: Multi II IV Vi Tab, Multi Plex I - TabCategories: Vitamin B Complex
  6. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali. … Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

    Mixtures: Kisqali Femara Co-pack, Kisqali Femara Co-packCategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates
  7. Drug

    Cilazapril

    go.drugbank.com/drugs/DB01340
    ApprovedInvestigational

    It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States. … Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs.

    Mixtures: INHIBACE PLUS 5 MG TABLET, 28 ADET, Inhibace plus 5 mg/12,5 mg - FilmtablettenCategories: Agents Acting on the Renin-Angiotensin System, P-glycoprotein inhibitors
  8. Target

    Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN

    go.drugbank.com/bio_entities/BE0005530
    TargetHumans

    Involved in the regulation of synaptic function in excitatory hippocampal synapses. … May be a negative regulator of insulin signaling and glucose metabolism in adipose tissue.

    Synonyms: Mutated in multiple advanced cancers 1
  9. Target

    tRNA-dihydrouridine(20) synthase [NAD(P)+]-like

    go.drugbank.com/bio_entities/BE0020091
    EnzymeHumans

    Specifically modifies U20 in cytoplasmic tRNAs (PubMed:38680565). Activity depends on the presence of guanosine at position 19 in the tRNA substrate (PubMed:38680565). … Catalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs (PubMed:15994936, PubMed:26429968, PubMed:30149704, PubMed:34798057, PubMed:38680565).

    Synonyms: Up-regulated in lung cancer protein 8
  10. Drug

    Chlorprothixene

    go.drugbank.com/drugs/DB01239
    ApprovedInvestigationalWithdrawn

    Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. … Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors.

    Categories: Dopamine D2 Receptor Antagonists, P-glycoprotein inhibitors